J&J’s second-quarter growth was driven by sales across pharma, medical device and consumer health divisions. Credit: Nikopoley / Wikimedia.

Johnson & Johnson (J&J) has reported sales of $23.31bn in the second quarter (Q2) of 2021, an increase of 27.1% compared to $18.33bn in the same quarter last year.

Net earnings for Q2 2021 stood at $6.28bn, a surge of 73.1% against $3.63bn during the year-ago quarter.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The diluted earnings per share (EPS) increased from $1.36 in Q2 2020 to $2.35 in Q2 2021, indicating a growth of 72.8%. Adjusted diluted EPS rose by 48.5% to $2.48 this year.

In the US, J&J’s reported sales grew by 24.9% to $11.91bn in the second quarter of this year as against $9.5bn last year.

This quarter’s international and worldwide sales grew by 29.5% and 27.1%, respectively.

In the pharmaceutical segment, the company recorded a 17.2% increase in sales to $12.6bn in Q2 2021 compared to $10.75bn in the same quarter last year.

J&J noted that the pharmaceutical global operational sales, excluding the net impact of acquisitions and divestitures, rose by 14.1%.

This growth was driven by various drugs, namely Stelara, Darzalex, Tremfya, Erleada, Imbruvica and Invega Sustenna/Xeplion/Invega Trinza/Trevicta (paliperidone palmitate).

The medical devices and consumer health businesses had a rise of 62.7% and 13.3%, respectively, in the reported sale this quarter.

Global sales also rose by 27.1% to $23.3bn in Q2 2021 from $18.3bn last year.

J&J increased its 2021 full-year guidance for operational sales to $90bn to $90.8bn and $92.5bn to $93.3bn, including Covid-19 vaccine sales, from $89.3bn $90.3bn in April.

Furthermore, the company increased the diluted adjusted EPS to $9.60 to $9.70 from $9.42 to $9.57.

Johnson & Johnson chairman and CEO Alex Gorsky said: “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our medical device, consumer health and pharmaceutical businesses.”

Separately, Johnson & Johnson and its subsidiary Janssen Pharmaceutical have agreed to pay up to $5bn to settle the alleged opioid claims in the US.

The development will resolve the ongoing lawsuit filed by the New York attorney-general Letitia James against companies that contributed to the opioid crisis in the country.

J&J’s deal is part of a $26bn agreement proposed to settle claims against various drug distributors and manufacturers.